Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Diethylstilbestrol→

Diethylstilbestrol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
56-53-1
Molecular formula
C18H20O2
Molecular weight
268.3502 g/mol
Drug class
Synthetic non-steroidal oestrogenestrogen receptor agonist (historical agent)
Mechanism of action
Activates estrogen receptors and regulates oestrogen-responsive gene transcription. It is a potent synthetic oestrogen with historical prenatal exposure-related adverse effects and current use limited to specific exceptional indications.
Indications / reported uses
  • Historical treatment of prostate cancer and selected breast cancer settings; use has been largely replaced by safer therapies. Prenatal exposure is associated with clear-cell adenocarcinoma and reproductive tract abnormalities in offspring, and it should not be presented as a routine contemporary oestrogen therapy.

Sources: NCI — Diethylstilbestrol (DES) exposure and cancer risk · NLM MeSH — Diethylstilbestrol · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Diethylstilbestrol Environmental Risk Assessment (ERA) (the Diethylstilbestrol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.